The Experts below are selected from a list of 7437 Experts worldwide ranked by ideXlab platform
Maldonado Rafael - One of the best experts on this subject based on the ideXlab platform.
-
Early $5-HT_{6}$ receptor blockade prevents symptom onset in a model of adolescent Cannabis Abuse
'EMBO', 2020Co-Authors: Berthoux Coralie, Hamieh, Al Mahdy, Rogliardo Angelina, Doucet, Emilie L., Coudert Camille, Ango Fabrice, Grychowska Katarzyna, Chaumont-dubel Séverine, Zajdel Paweł, Maldonado RafaelAbstract:Cannabis Abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of $5-HT_{6}$ receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of $\Delta9$-tetrahydrocannabinol (THC) to mice during adolescence induces a longlasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a $5-HT_{6}$ receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of $5-HT_{6}$ receptor-operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of $5-HT_{6}$ receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent Cannabis Abusers
-
Early 5‐ HT 6 receptor blockade prevents symptom onset in a model of adolescent Cannabis Abuse
'EMBO', 2020Co-Authors: Berthoux Coralie, Hamieh, Al Mahdy, Rogliardo Angelina, Coudert Camille, Ango Fabrice, Grychowska Katarzyna, Chaumont-dubel Séverine, Doucet Emilie, Zajdel Pawel, Maldonado RafaelAbstract:International audienceCannabis Abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of ∆9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a 5-HT6 receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of 5-HT6 receptor-operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5-HT6 receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent Cannabis Abusers
Merete Nordentoft - One of the best experts on this subject based on the ideXlab platform.
-
INTERIM ANALYSIS OF THE CAPOPUS TRIAL: A RANDOMIZED, PARALLEL-GROUP, OBSERVER-BLINDED CLINICAL TRIAL OF SPECIALIZED ADDICTION TREATMENT VERSUS TREATMENT AS USUAL FOR YOUNG PATIENTS WITH Cannabis Abuse AND PSYCHOSIS
Schizophrenia Research, 2010Co-Authors: Carsten Hjorthøj, Allan Fohlmann, Anne-mette Larsen, Mette Madsen, Lone Vesterager, Christian Gluud, Mikkel Arendt, Merete NordentoftAbstract:Background: A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. Objectives: The major objective for the CapOpus trial is to evaluate the additional effect on Cannabis Abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. Design: The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of Cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. Trial registration: ClinicalTrials.gov NCT00484302.
-
p03 179 capopus trial an observer blinded rct of specialized addiction treatment versus standard treatment for young patients with Cannabis Abuse and psychosis
European Psychiatry, 2009Co-Authors: Merete Nordentoft, Carsten Hjorthøj, Allan FohlmannAbstract:Background A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. Objectives The major objective for the CapOpus trial is to evaluate the effects of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual compared with just treatment as usual. Design The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are recruited through teams for early detection of people with psychosis, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1. specialized addiction treatment plus treatment as usual or 2. treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case-manager of the patient. The primary outcome measurement will be amount of reduction in Cannabis consumption. Other outcome measures will be improvements in psychosis symptoms, cognitive functioning, quality of life and social functioning, and cost-benefit of the treatments.
-
Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with Cannabis Abuse and psychosis
Trials, 2008Co-Authors: Carsten Hjorthøj, Allan Fohlmann, Anne-mette Larsen, Mette Madsen, Lone Vesterager, Christian Gluud, Mikkel Arendt, Merete NordentoftAbstract:A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. The major objective for the CapOpus trial is to evaluate the additional effect on Cannabis Abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of Cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. ClinicalTrials.gov NCT00484302.
Rainer Hellweg - One of the best experts on this subject based on the ideXlab platform.
-
brain derived neurotrophic factor serum concentrations are increased in drug naive schizophrenic patients with chronic Cannabis Abuse and multiple substance Abuse
Neuroscience Letters, 2004Co-Authors: Maria C Jockersscherubl, Heidi Dankerhopfe, Undine E Lang, Richard Mahlberg, Franziska Selig, Johannes Rentzsch, Falk Schurer, Rainer HellwegAbstract:Neurotrophins such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are critically implicated in development and maintenance of function of neurons. Neurodevelopment is reported to be impaired in schizophrenia and vulnerable schizophrenic brains may be more sensitive to toxic influences. Thus, Cannabis as a neurotoxin, may be more harmful to schizophrenic brains than to non-schizophrenic brains when used chronically. And neurotoxic events may promote disease-onset and lead to exaggerated release of neurotrophins. We investigated 157 drug-naive first-episode schizophrenic patients and found significantly elevated BDNF serum concentrations (by up to 34%) in patients with chronic Cannabis Abuse (n = 35, p < 0.001) or multiple substance Abuse (n = 20, p < 0.001) prior to disease onset. Drug-naive schizophrenic patients without Cannabis consumption showed similar results to normal controls and Cannabis controls without schizophrenia. Thus, raised BDNF serum levels are not related to schizophrenia and/or substance Abuse itself but may reflect a Cannabis-related idiosyncratic damage of the schizophrenic brain. In line with this hypothesis, disease onset was 5.2 years earlier in the Cannabis-consuming group (p = 0.0111).
-
chronic Cannabis Abuse raises nerve growth factor serum concentrations in drug naive schizophrenic patients
Journal of Psychopharmacology, 2003Co-Authors: Maria C Jockersscherubl, Uta Matthies, Heidi Dankerhopfe, Undine E Lang, Richard Mahlberg, Rainer HellwegAbstract:Long-term Cannabis Abuse may increase the risk of schizophrenia. Nerve growth factor (NGF) is a pleiotropic neurotrophic protein that is implicated in development, protection and regeneration of NFG-sensitive neurones. We tested the hypothesis that damage to neuronal cells in schizophrenia is precipitated by the consumption of Cannabis and other neurotoxic substances, resulting in raised NGF serum concentrations and a younger age for disease onset. The NGF serum levels of 109 consecutive drug-naive schizophrenic patients were measured and compared with those of healthy controls. The results were correlated with the long-term intake of Cannabis and other illegal drugs. Mean (+/- SD) NGF serum levels of 61 control persons (33.1 +/- 31.0 pg/ml) and 76 schizophrenics who did not consume illegal drugs (26.3 +/- 19.5 pg/ml) did not differ significantly. Schizophrenic patients with regular Cannabis intake (> 0.5 g on average per day for at least 2 years) had significantly raised NGF serum levels of 412.9 +/- 288.4 pg/ml (n = 21) compared to controls and schizophrenic patients not consuming Cannabis (p < 0.001). In schizophrenic patients who Abused not only Cannabis, but also additional substances, NGF concentrations were as high as 2336.2 +/- 1711.4 pg/ml (n = 12). On average, heavy Cannabis consumers suffered their first episode of schizophrenia 3.5 years (n = 21) earlier than schizophrenic patients who abstained from Cannabis. These results indicate that Cannabis is a possible risk factor for the development of schizophrenia. This might be reflected in the raised NGF-serum concentrations when both schizophrenia and long-term Cannabis Abuse prevail.
Berthoux Coralie - One of the best experts on this subject based on the ideXlab platform.
-
Early $5-HT_{6}$ receptor blockade prevents symptom onset in a model of adolescent Cannabis Abuse
'EMBO', 2020Co-Authors: Berthoux Coralie, Hamieh, Al Mahdy, Rogliardo Angelina, Doucet, Emilie L., Coudert Camille, Ango Fabrice, Grychowska Katarzyna, Chaumont-dubel Séverine, Zajdel Paweł, Maldonado RafaelAbstract:Cannabis Abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of $5-HT_{6}$ receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of $\Delta9$-tetrahydrocannabinol (THC) to mice during adolescence induces a longlasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a $5-HT_{6}$ receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of $5-HT_{6}$ receptor-operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of $5-HT_{6}$ receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent Cannabis Abusers
-
Early 5‐ HT 6 receptor blockade prevents symptom onset in a model of adolescent Cannabis Abuse
'EMBO', 2020Co-Authors: Berthoux Coralie, Hamieh, Al Mahdy, Rogliardo Angelina, Coudert Camille, Ango Fabrice, Grychowska Katarzyna, Chaumont-dubel Séverine, Doucet Emilie, Zajdel Pawel, Maldonado RafaelAbstract:International audienceCannabis Abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of ∆9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a 5-HT6 receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of 5-HT6 receptor-operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5-HT6 receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent Cannabis Abusers
Allan Fohlmann - One of the best experts on this subject based on the ideXlab platform.
-
INTERIM ANALYSIS OF THE CAPOPUS TRIAL: A RANDOMIZED, PARALLEL-GROUP, OBSERVER-BLINDED CLINICAL TRIAL OF SPECIALIZED ADDICTION TREATMENT VERSUS TREATMENT AS USUAL FOR YOUNG PATIENTS WITH Cannabis Abuse AND PSYCHOSIS
Schizophrenia Research, 2010Co-Authors: Carsten Hjorthøj, Allan Fohlmann, Anne-mette Larsen, Mette Madsen, Lone Vesterager, Christian Gluud, Mikkel Arendt, Merete NordentoftAbstract:Background: A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. Objectives: The major objective for the CapOpus trial is to evaluate the additional effect on Cannabis Abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. Design: The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of Cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. Trial registration: ClinicalTrials.gov NCT00484302.
-
p03 179 capopus trial an observer blinded rct of specialized addiction treatment versus standard treatment for young patients with Cannabis Abuse and psychosis
European Psychiatry, 2009Co-Authors: Merete Nordentoft, Carsten Hjorthøj, Allan FohlmannAbstract:Background A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. Objectives The major objective for the CapOpus trial is to evaluate the effects of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual compared with just treatment as usual. Design The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are recruited through teams for early detection of people with psychosis, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1. specialized addiction treatment plus treatment as usual or 2. treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case-manager of the patient. The primary outcome measurement will be amount of reduction in Cannabis consumption. Other outcome measures will be improvements in psychosis symptoms, cognitive functioning, quality of life and social functioning, and cost-benefit of the treatments.
-
Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with Cannabis Abuse and psychosis
Trials, 2008Co-Authors: Carsten Hjorthøj, Allan Fohlmann, Anne-mette Larsen, Mette Madsen, Lone Vesterager, Christian Gluud, Mikkel Arendt, Merete NordentoftAbstract:A number of studies indicate a link between Cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat Cannabis Abuse among patients with psychosis. The major objective for the CapOpus trial is to evaluate the additional effect on Cannabis Abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of Cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. ClinicalTrials.gov NCT00484302.
